NEW YORK (GenomeWeb) – The New York Genome Center has named Carol Ashe its new chief business officer. She previously served as VP of corporate development for pharmaceutical firm Endo International, and prior to that was a partner at GlaxoSmithKline's venture capital fund, SR One. Ashe also led GSK's US corporate legal group, which supported M&A transactions and the business development legal transactions team.

She holds a bachelor's degree in biology from Pennsylvania State University and a law degree from the Villanova University School of Law.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.